SPECIAL DEPARTMENTSписьмо
Аннотация: Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.1.235 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10623717 Jean-Pierre Pignon Michel DucreuxxJean-Pierre Pignon Michel DucreuxSearch for articles by this author , Philippe RougierxPhilippe RougierSearch for articles by this author Charles ErlichmanxCharles ErlichmanSearch for articles by this author Show More Institut Gustave-Roussy VillejuifFranceHôpital Ambroise-Paré BoulogneFranceOn behalf of the IMPACT B2 Investigators Mayo Clinic RochesterMN https://doi.org/10.1200/JCO.2000.18.1.235 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01012000In Reply:Pignon et al suggest that comparing the efficacy in stage II and III patients would have increased the power of our study. I refer them to the publication in the Lancet in 1995,1 in which a complete analysis of the total population was undertaken. In this publication, there was a statistically significant difference between the total populations treated with fluorouracil/leucovorin versus the controls and in the subset of stage III patients. At the time we did that analysis, there were insufficient events to allow an analysis of the stage II patients. The recent publication2 in the Journal of Clinical Oncology reflects the analysis when sufficient events had occurred, such that an analysis was appropriate.We could have updated the analysis for the whole population and then done a separate analysis for the stage II and III patients. However, this exercise would not have increased our power to address the question of whether fluorouracil and leucovorin had any benefit in patients with stage II colon cancer. The only way we can potentially increase the power of this study is to undertake another analysis with longer follow-up of the stage II subset. As far as the publication of the meta-analysis performed by the Colorectal Cancer Collaborative Group is concerned, it is not clear whether the question will be settled by such an analysis if there are multiple treatment regimens in which the chemotherapy is being used, which would make it more difficult to sort out whether fluorouracil/leucovorin, specifically, is useful in stage II colon cancer.3. The IMPACT Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. Lancet 345::939,1995-944, Crossref, Medline, Google Scholar3. International Multicentre Pooled Analysis of B2 Colon Cancer Treatment (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17::1356,1999-1363, Link, Google Scholar
Год издания: 2000
Издательство: Lippincott Williams & Wilkins
Источник: Journal of Clinical Oncology
Ключевые слова: Genetic factors in colorectal cancer, Colorectal Cancer Treatments and Studies, Colorectal and Anal Carcinomas
Другие ссылки: Journal of Clinical Oncology (HTML)
PubMed (HTML)
PubMed (HTML)
Открытый доступ: closed
Том: 18
Выпуск: 1
Страницы: 235–a